In particular, we demonstrated that ErbB2-overexpressing cancer cells are preferentially responsive to ganetespib, and that ganetespib significantly potentiates lapatinib-mediated anti-cancer effects in ErbB2+ breast cancer cells. This evidence concerns the gene ERBB2 and breast cancer.